the hire insures "trade secrets" and "IP rights" are kept in-house vs. being acquired by a competitor/big tobacco; and, propels XXII into more research on altering marijuana plants for optimal benefit(?). Possibly even enhancement of the "pain management" aspects of #$%$...lots of options with the "plant genetics expert" onboard. great decision, imo.
and it's not even the premier anti-addiction brand...can you say (one day) HOLY SIMMERING VOLCANO!?!?!?
from NIH/Drub Abuse/Tobacco & Nicotine website...
Twin women smiling.Twin studies indicate that approximately 40–70 percent of a person’s risk of becoming addicted to nicotine depends on his or her genes. If so many smokers want to quit, why are few able to do so successfully? To address this question, scientists are increasingly focusing on the powerful role of genetics in addiction. Twin studies indicate that approximately 40–70 percent of a person’s risk of becoming addicted to nicotine depends on his or her genes. Although complex diseases like addiction involve large numbers of genes interacting with a wide variety of environmental factors, the contribution of a particular gene can be substantial.
Genetic variants associated with nicotine metabolism, for example, have been shown to influence how people smoke. Slow metabolizers smoke fewer cigarettes per day and have a higher likelihood of quitting, and that there is greater abstinence among individuals receiving nicotine patch therapy. A recent NIDA-funded study identified a variant in the gene for a nicotinic receptor subunit that doubled the risk for nicotine addiction among smokers. A subsequent study found that this gene variant also increased susceptibility to the severe health consequences of smoking, including lung cancer and peripheral arterial disease. NIDA is currently supporting large-scale genome-wide association studies to uncover additional genetic risk factors in order to better understand tobacco addiction and its adverse effects on health.
In addition to predicting an individual’s risk for nicotine addiction, genetic markers can also help predict whether medications (like bupropion) will effectively help a smoker quit. This takes root in the emerging field of pharmacogenomics, which investigates how genes influence a patient’s response to drugs and medications. In the future, genetic screening could help clinicians select treatments, adjust dosages, and avoid or minimize adverse reactions, tailoring smoking cessation therapies to an indiv
fyi, when a negative such as -$0.07 gets smaller, such as going to -$0.03, it is INCREASING...becoming "less negative"...the LOSS decreased, but the earnings did not.
...anyone have more detail?
ignorance must be fun..."Mark" has already proven he can cut expenses...where have you been? Cash on the balance sheet is also impressive, so...you were saying?
imo, this creativity is what we need from management - more ad revenue via non-traditional means. Kudos to the creative geniuses at ZNGA!
to all the Vivus haters out there, this move has the potential to bring longs back from the depths of despair!!!!! Like a freakin' lifeboat to a deserted island after a shipwreck. We have been SAVED!!!! SOS, CARL, SOS!!!! lol...
gonna fry a LOT of shorts along the way...good riddance.
RBC Capital analyst Simos Simeonidis appears to be the only sell-sider to comment on the news and he thinks it is a "very significant positive."
Simeonidis notes Icahn has had the "golden touch" in biotech and notes the connection to Vivus board member Dr. Alex Denner.
"Even though Mr. Icahn is known as a fierce street brawler, and has been very successful in that regard in other industries, the vast majority of his most successful company turnarounds in biotech have been during the tenure of the much more diplomatic, bridge-building lieutenant Dr. Alex Denner," he commented.
Icahn's success stories with Denner involved include: Imclone, Genzyme, Amylin and Biogen to name just a few, the analyst highlighted.
"There are however plenty of others, where the approachable and softer-speaking Denner was able to get to a desired outcome without a public fight," he commented. "Mr. Icahn has not been as involved in biotech since Dr. Denner departed to start his own fund, Sarissa Capital. Given the latter's 2.6M share position in VVUS, it looks like they may be getting the band together for this one."
Commenting on what is next for Vivus, Simeonidis reminds investors that Dr. Denner is on the board of Vivus and was part of the effort to unseat prior management. "In the past, part of the Denner/Icahn playbook in biotech had been to look for mismanaged teams and undervalued companies, and force a sale to a larger company," he commented. "This could be a definite possibility here, especially given Denner's deep contacts in the biopharma industry, despite the fact that the branded obesity market has been a disappointment, taking much longer to develop and the company's IP has long been in question."
Further the analyst notes that the following happened two years ago today - "And speaking of IP, it is perhaps worth noting the name of the CEO of one of the two companies (Actavis) that had challenged Qsymia's patents: it is Brent Saunders, and two years ago tomorrow (on 9/10/13) he was appointed CEO of Forest Labs. You may recall who his backer was in the very difficult fight to replace then CEO Howard Solomon..." (answer = Icahn)
While Simeonidis notes while Qsymia sales have been disappointing, to say the least, Qsymia is the best branded obesity agent approved. He views the stock as attractive at current levels. He maintained an Outperform rating and price target of $4 on VVUS.
there's no doubt it should already be the leader...who doesn't want a better "mouse trap"?!?!?!?!? the marketing of Stendra/Spedra, as well as Q, was mismanaged, imo, or we'd have seen unparalleled growth in revenues by now. Let's see what the future holds with Icahn involved...my guess it won't be long before we see the turbo-thrusters turned up.